Patents Assigned to GAN & LEE PHARMACEUTICALS
-
Patent number: 11787801Abstract: The embodiments disclosed herein provide compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, wherein R1 to R7 are as defined in the description. This application also provides a preparation method and a medical use of the compounds. The compounds of this disclosure have an activity superior or equivalent to the candidate drug LY2835219 currently under phase III clinical trial, and some of the compounds exhibit better selectivity. Moreover, the preferred compounds exhibit good absorption and good blood-brain distribution when administered orally.Type: GrantFiled: July 30, 2021Date of Patent: October 17, 2023Assignee: Gan & Lee PharmaceuticalsInventors: Lei Yin, Wenjian Liu, Heng Li, Dianxi Zhu
-
Patent number: 11339171Abstract: A compound capable of being used as a tumor inhibitor, a preparation method therefor, and application thereof. The compound has a structure represented by general formula I; a stereoisomer, an enantiomer, a raceme, a cis/trans isomer, a tautomer, and an isotopic variant of the compound are comprised; the compound can be used separately or in combination with other drugs for treating tumors or inflammatory diseases, or for treating other disorders or diseases mediated by the activity of MDM2 and/or MDM4, and shows prominent curative activity.Type: GrantFiled: December 21, 2018Date of Patent: May 24, 2022Assignee: Gan & Lee PharmaceuticalsInventors: Yin Lei, Yao Zhenglin, Li Heng
-
Patent number: 11091476Abstract: The embodiments disclosed herein provide compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, wherein R1 to R7 are as defined in the description. This application also provides a preparation method and a medical use of the compounds. The compounds of this disclosure have an activity superior or equivalent to the candidate drug LY2835219 currently under phase III clinical trial, and some of the compounds exhibit better selectivity. Moreover, the preferred compounds exhibit good absorption and good blood-brain distribution when administered orally.Type: GrantFiled: November 28, 2016Date of Patent: August 17, 2021Assignee: Gan & Lee PharmaceuticalsInventors: Lei Yin, Wenjian Liu, Heng Li, Dianxi Zhu
-
Publication number: 20210079007Abstract: A compound capable of being used as a tumor inhibitor, a preparation method therefor, and application thereof. The compound has a structure represented by general formula I; a stereoisomer, an enantiomer, a raceme, a cis/trans isomer, a tautomer, and an isotopic variant of the compound are comprised; the compound can be used separately or in combination with other drugs for treating tumors or inflammatory diseases, or for treating other disorders or diseases mediated by the activity of MDM2 and/or MDM4, and shows prominent curative activity.Type: ApplicationFiled: December 21, 2018Publication date: March 18, 2021Applicant: Gan & Lee PharmaceuticalsInventors: Yin Lei, Yao Zhenglin, Li Heng
-
Patent number: 10696678Abstract: The invention provides a compound of Formula I, or its tautomer, mesomer, racemate, enantiomer, diastereoisomer or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compound of Formula I, its tautomer, mesomer, racemate, enantiomer, or diastereoisomer. Ring A, R1, R2, R3 and R4 are as defined in the specification. The invention further provides a method for preparing the compound of Formula I and their use in the manufacture of a medicament for the treatment of a cell proliferative disorder.Type: GrantFiled: October 20, 2016Date of Patent: June 30, 2020Assignee: GAN & LEE PHARMACEUTICALSInventors: Wenjian Liu, Lei Yin, Heng Li
-
Patent number: 9187520Abstract: Disclosed is a method for preparing an insulin glargine (GlyA21-ArgB31-AryB32-human insulin) crystal, comprising crystallizing the insulin glargine at pH 7.0-9.0 and in a crystallization solution containing a recombinant insulin glargine, an organic solvent of a 10-30% concentration by volume, a zinc compound, a phenol derivative, a salt and an organic acid.Type: GrantFiled: April 19, 2012Date of Patent: November 17, 2015Assignee: Gan & Lee PharmaceuticalsInventors: Damei Wang, Wenjie Li, Jinlei Zhang
-
Publication number: 20140155574Abstract: Disclosed is a method for preparing an insulin glargine (GlyA21-ArgB31-AryB32-human insulin) crystal, comprising crystallizing the insulin glargine at pH 7.0-9.0 and in a crystallization solution containing a recombinant insulin glargine, an organic solvent of a 10-30% concentration by volume, a zinc compound, a phenol derivative, a salt and an organic acid.Type: ApplicationFiled: April 19, 2012Publication date: June 5, 2014Applicant: GAN & LEE PHARMACEUTICALSInventors: Damei Wang, Wenjie Li, Jinlei Zhang